Inotiv Faces Going Concern Doubts Amidst Debt, Weak Controls, and NHP Supply Woes

Ticker: NOTV · Form: 10-K · Filed: Dec 5, 2025 · CIK: 720154

Sentiment: bearish

Topics: CRO, Biotechnology, Pharmaceutical, Going Concern, Internal Controls, Debt, Cybersecurity

TL;DR

**Inotiv is on life support, battling massive debt, internal control failures, and a collapsing NHP market; steer clear unless you're a high-risk speculator.**

AI Summary

Inotiv, Inc. (NOTV) filed its 10-K for the fiscal year ended September 30, 2025, revealing significant financial and operational challenges. The company, a contract research organization, reported conditions that raise substantial doubt about its ability to continue as a going concern, stemming from periods of losses and financial insecurity. A key risk highlighted is significant indebtedness and the potential inability to service debt or comply with Credit Agreement covenants, which restrict business and financing activities. Furthermore, management concluded that disclosure controls and internal control over financial reporting were ineffective as of September 30, 2025, due to material weaknesses. The company also faces adverse impacts from its dependence on non-human primate (NHP) imports, particularly from Southeast Asia and Africa, with NHP sales decreasing significantly. Inotiv is involved in legal proceedings and is at risk of further cyber-attacks, including a 2025 Cybersecurity Incident, which could compromise sensitive information and expose it to liability.

Why It Matters

Inotiv's 10-K filing signals deep financial distress, with management explicitly stating conditions that raise substantial doubt about its ability to continue as a going concern. This directly impacts investors through potential stock price volatility and dilution risks if new capital is sought. For employees, the uncertainty could lead to job insecurity, while customers, particularly in the pharmaceutical and medical device industries, face potential disruptions in critical drug discovery and development services. The company's struggles with NHP supply and cybersecurity also highlight broader industry vulnerabilities, especially for CROs reliant on global supply chains and robust data protection, potentially shifting competitive dynamics towards more stable providers.

Risk Assessment

Risk Level: high — The risk level is high due to explicit statements in the filing, including management's conclusion that 'conditions and events that could raise substantial doubt about our ability to continue as a going concern' exist. Additionally, the company reported 'material weaknesses in internal control over financial reporting' as of September 30, 2025, and acknowledged 'significant indebtedness' that may impair its ability to raise capital or service debt, indicating severe operational and financial instability.

Analyst Insight

Investors should exercise extreme caution and consider divesting NOTV shares due to the explicit 'going concern' warning and material weaknesses in internal controls. Potential investors should avoid initiating new positions until significant improvements in financial stability and operational controls are demonstrated, as the risks outlined are fundamental to the company's survival.

Financial Highlights

debt To Equity
Not Disclosed
revenue
Not Disclosed
operating Margin
Not Disclosed
total Assets
Not Disclosed
total Debt
Not Disclosed
net Income
Not Disclosed
eps
Not Disclosed
gross Margin
Not Disclosed
cash Position
Not Disclosed
revenue Growth
Not Disclosed

Revenue Breakdown

SegmentRevenueGrowth
Discovery and Safety Assessment (DSA)Not DisclosedNot Disclosed
Research Models and Services (RMS)Not DisclosedNot Disclosed

Key Numbers

Key Players & Entities

FAQ

What are the primary financial concerns for Inotiv, Inc. as per its 2025 10-K filing?

Inotiv, Inc.'s 2025 10-K filing highlights substantial doubt about its ability to continue as a going concern, significant indebtedness that may impair capital raising, and a conclusion by management that disclosure controls and internal control over financial reporting were ineffective as of September 30, 2025.

How has Inotiv's dependence on non-human primates impacted its business?

Inotiv's business has been adversely affected by its dependence on non-human primates (NHPs) from suppliers outside the U.S., particularly from Southeast Asia and Africa. The company has experienced a significant decrease in NHP sales in recent periods, impacting its financial condition and results of operations.

What is the status of Inotiv's internal controls over financial reporting?

As of September 30, 2025, Inotiv's management concluded that its disclosure controls and procedures and its internal control over financial reporting were not effective due to identified material weaknesses. This could affect the accuracy and timeliness of its financial reporting.

What are the risks associated with Inotiv's indebtedness?

Inotiv's significant indebtedness may impair its ability to raise additional capital or service its existing debt. The Credit Agreement contains covenants that restrict business and financing activities, and failure to comply could result in an event of default, materially adversely affecting the company.

What legal and regulatory challenges does Inotiv face?

Inotiv is involved in legal proceedings that could adversely affect its business and is subject to inspections, investigations, and enforcement actions by regulatory authorities. The company also faces compliance requirements related to environmental, health, and safety, and data privacy laws.

What impact do cyber-attacks have on Inotiv's operations?

Inotiv has experienced and is at risk of further cyber-attacks, including a '2025 Cybersecurity Incident,' which could compromise sensitive business and personal information. Such breaches could undermine its ability to operate effectively, expose it to liability, and harm its business and reputation.

What are Inotiv's two main business segments?

Inotiv operates with two reportable segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment provides nonclinical and clinical development services, while the RMS segment offers research-quality animals, diets, and related services.

How does government funding affect Inotiv's business?

Some of Inotiv's clients and contracts depend on government funding for research and development. A reduction in this funding, or disruptions at agencies like the U.S. Food and Drug Administration (FDA) due to funding shortages, could adversely affect demand for Inotiv's services and products.

What is the market value of Inotiv's common equity held by non-affiliates?

As of March 31, 2025, the aggregate market value of the voting and non-voting common equity held by non-affiliates of Inotiv, Inc. was $71,278,516.

What is Inotiv's strategic outlook regarding acquisitions and growth?

Inotiv has expanded and may further expand its business through acquisitions, which exposes it to various risks, including the failure to identify all pertinent risks during due diligence or to realize anticipated strategic and financial benefits from these integrations and its site optimization strategy.

Risk Factors

Industry Context

Inotiv operates as a contract research organization (CRO) serving the pharmaceutical and medical device industries. The CRO market is competitive, driven by the increasing outsourcing of R&D activities by life sciences companies seeking to reduce costs and accelerate drug development timelines. Key trends include demand for specialized services, advanced technologies, and reliable animal models. However, the industry is also subject to stringent regulatory oversight and ethical considerations regarding animal research.

Regulatory Implications

Inotiv faces regulatory scrutiny related to its operations, particularly concerning the import and use of non-human primates (NHPs). The company's conclusion of ineffective internal controls over financial reporting also implies potential future regulatory challenges if material weaknesses are not remediated. Compliance with Good Laboratory Practice (GLP) standards is essential for its safety assessment services.

What Investors Should Do

  1. Monitor NHP import regulations and supply chain stability.
  2. Track progress on remediation of material weaknesses in internal controls.
  3. Assess the company's ability to manage its debt obligations and comply with covenants.
  4. Evaluate the impact of the cybersecurity incident and ongoing cyber risks.
  5. Scrutinize any future capital raise efforts.

Key Dates

Glossary

Contract Research Organization (CRO)
A company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. (Inotiv operates as a CRO, offering drug discovery and development services.)
Going Concern
An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (Substantial doubt about Inotiv's ability to continue as a going concern is a critical warning sign for investors.)
Material Weaknesses
A deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (The existence of material weaknesses in Inotiv's controls raises concerns about the reliability of its financial reporting.)
Non-human primates (NHPs)
Primates, such as monkeys and apes, used in scientific research, particularly in preclinical testing of drugs and vaccines. (Inotiv's significant dependence on NHP imports and the recent decrease in NHP sales are key operational and financial challenges.)
Credit Agreement
A contract between a borrower and a lender that details the terms and conditions of a loan. (Inotiv's Credit Agreement contains covenants that restrict its business and financing activities, posing a risk.)
Good Laboratory Practice (GLP)
A quality system concerned with the organization and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, reported and archived. (Inotiv's DSA segment operates under GLP standards, indicating adherence to regulatory quality requirements for safety assessments.)
Discovery and Safety Assessment (DSA)
A business segment of Inotiv providing services related to drug discovery, translational sciences, and safety assessment. (This segment is a core part of Inotiv's service offerings to the pharmaceutical and medical device industries.)
Research Models and Services (RMS)
A business segment of Inotiv that provides animal research models and related services. (This segment is crucial for supplying research animals, a key component of Inotiv's business, which has faced challenges with NHP sales.)

Year-Over-Year Comparison

The 10-K for the fiscal year ended September 30, 2025, indicates a significant deterioration in Inotiv's financial health compared to the previous year. Key concerns include the explicit statement of substantial doubt about the company's ability to continue as a going concern, a situation not highlighted to this degree previously. Furthermore, the conclusion of ineffective internal controls over financial reporting due to material weaknesses is a new and critical development. While specific financial metrics like revenue growth and margins are not detailed in the provided text for comparison, the emphasis on significant indebtedness, restrictive covenants, and decreased NHP sales points to heightened financial and operational risks.

Filing Stats: 4,405 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2025-12-05 08:53:02

Key Financial Figures

Filing Documents

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 22 Item 1B. Unresolved Staff Comments 40 Item 1C. Cybersecurity 40 Item 2.

Properties

Properties 41 Item 3.

Legal Proceedings

Legal Proceedings 41 Item 4. Mine Safety Disclosures 41 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 41 Item 6. [Reserved] 42 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 42 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 67 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 68 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 123 Item 9A.

Controls and Procedures

Controls and Procedures 123 Item 9B. Other Information 125 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 125 PART III Item 10. Directors, Executive Officers and Corporate Governance 125 Item 11.

Executive Compensation

Executive Compensation 126 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 126 Item 13. Certain Relationships and Related Transactions, and Director Independence 126 Item 14. Principal Accountant Fees and Services 126 PART IV Item 15. Exhibits and Financial Statement Schedules 127 Item 16. Form 10-K Summary 127 3 Table of Contents RISK FACTORS SUMMARY Our business is subject to many risks and uncertainties, which, if they occur, could adversely affect our business and financial performance or condition, our actual results could differ materially from our expectations and the market value of our stock could decline. We have provided a summary of some of these risks below, with more information in Part I, Item 1A. "Risk Factors" of this Annual Report on Form 10-K. We have identified conditions and events that could raise substantial doubt about our ability to continue as a going concern. We have experienced periods of losses and financial insecurity. We have significant indebtedness, which may impair our ability to raise capital or impact our ability to service our debt. Our Credit Agreement contains covenants that restrict our business and financing activities. Our assets secure our obligations under the Credit Agreement and the Second Lien Notes and may be subject to foreclosure. Our failure to comply with the terms of our Credit Agreement could result in an event of default that could materially adversely affect our business, financial condition and results of operations. We may need additional capital, and any additional capital we seek may not be available in the amount or at the time we need it. Our management concluded that our disclosure controls and procedures and our internal control over financial reporting were not effective as of September 30, 2025 and as of prior dates due to material weaknesses in internal control over financial reporting. If we are unable to remediate these material weaknesses and ma

– BUSINESS

ITEM 1 – BUSINESS Corporate History Inotiv, Inc. and its subsidiaries ("we," "our," "us," the "Company," or "Inotiv") began operating in 1975 as Bioanalytical Systems, Inc. Bioanalytical Systems, Inc. was incorporated in 1974 and completed an initial public offering in 2000. On March 18, 2021, the Company changed its corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. Our stock is traded on The Nasdaq Stock Market LLC under the symbol "NOTV." We are headquartered in West Lafayette, Indiana. Our headquarters mailing address is 2701 Kent Avenue, West Lafayette, Indiana 47906, and the telephone number at that location is (765) 463-4527. Our Internet site is www.inotiv.com. The information contained on our website is not a part of this Report and is not incorporated by reference herein. Overview Inotiv is a leading contract research organization ("CRO") dedicated to providing nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries as well as academia and government clients. Our products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development and, in certain cases, the clinical phases of development, all while focusing on increasing efficiency, improving data, and reducing the cost of discovering and taking new drugs and medical devices to market. Inotiv is committed to supporting discovery 6 Table of Contents and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. We are dedicated to practicing high standards of laboratory animal care and welfare. We have two reportable segments: Discovery and Safety Assessment ("DSA") and Research Models and Services ("RMS"). Through our DSA segment, we

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing